Xylyx Bio is a biotechnology company with integrated research and development laboratories and manufacturing facilities. The company specializes in the development, manufacturing, and commercialization of tissue-derived decellularized extracellular matrix (dECM) kits and assays for human disease modeling and drug testing.
Leveraging its InMatrico® platform and TissueSpec® dECM product line, Xylyx Bio enables scientists to incorporate tissue-specific dECM into in-vitro models, enhancing physiological relevance and helping to bridge the gap between conventional laboratory models and human biology.